Clinical and pharmacological group:
Pharmacotherapeutic group :
Rebamipid increases the content of prostaglandin E2 (PGE2) in the gastric mucosa and increases the content of PGE2 and GI2 in the contents of gastric juice. It has a cytoprotective effect against the gastric mucosa with the damaging effects of ethanol, acids and alkalis, acetylsalicylic acid.
It promotes the activation of enzymes that accelerate the biosynthesis of high molecular weight glycoproteins, and increases the content of mucus on the surface of the stomach wall. It helps to improve the blood supply to the gastric mucosa, activates its barrier function, activates the alkaline secretion of the stomach, enhances the proliferation and metabolism of gastric epithelial cells, cleans the mucosa of hydroxyl radicals and suppresses superoxides produced by polymorphonuclear leukocytes and neutrophils in the presence of Helicobacter pylori, protects the mucosa from mucosa, protects the mucosa from mucosal infections has a gastroprotective effect when exposed to the mucosa of NSAIDs.
Suction and distribution
After administration at a dose of 100 mg, Cmax is reached after approximately 2 hours and is 340 ng / ml. Repeated doses of the drug do not lead to its cumulation in the body.
In vitro experiments have shown that from 98.4% to 98.6% of the drug binds to plasma proteins.
Metabolism and excretion ofT1 / 2 is approximately 1.0 hour. Approximately 10% of the drug is excreted by the kidneys, mainly unchanged. When taken in a dose of 600 mg, traces of a hydroxylated metabolite can be distinguished.